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To shed light on the future of photodynamic 
therapy (PDT) requires rational ana lysis of the 
current state of the art. No doubt, future PDT 
will build on current clinical successes as well 
as an enhanced understanding of its mecha-
nisms of action, which continue to be eluci-
dated. The discovery of PDT is attributed to 
Oscar Raab who was employing dyes to study 
paramecia [1]. In addition to helping discover 
fluorescence phenomena from these dyes, Raab 
also noted that upon occasion the paramecia 
would succumb following intense illumination. 
This phenomenon was not lost on Raab or his 
professor von Tappenier who elucidated the 
oxygen-dependent nature of what he termed the 
photodynamic reaction (PDR) [2]. Thus, PDT 
was born through a serendipitous observation 
and by 1907 was an oncologic therapy option [3]. 
Despite this early success, PDT did not flour-
ish, but did sporadically reappear in the clinical 
arena particularly in the late 1950s and early 
1960s [4]. This work focused more on fluores-
cence detection [4–7]. In the 1970s Dougherty, 
who had completed a distinguished career in 
chemistry, began a second career in radiation 
biology studying radiation sensitizing chemi-
cals. He joined a project already underway and 
was warned not to put the cell cultures near the 
windows when using select vital stains. When 
he asked why, he was told that the tumor cells 
would die when the added stain was exposed 
to light. Rather than following this advice, Dr 
Dougherty re-discovered PDT [8], and unlike 
those who came before, brought PDT to a 
worldwide audience by achieving regulatory 
approval, clinical indications and commercial 
production. For these efforts, he is honored 
as the father of PDT though, certainly, many 
members of this family exist. 
PDT in the clinic
As currently practiced, PDT achieves lesion 
ablation due to light activation of an applied 
photosensitizing agent, which, when in the 
presence of oxygen, ultimately generates the 
PDR [9]. This reaction, based on the genera-
tion of reactive oxygen species, results in rapid 
cytotoxic and vasculotoxic shutdown, which has 
been demonstrated to be highly successful as 
a tumor-ablative therapy. The relative simplic-
ity of drug activation by light leading to the 
PDR has allowed PDT to be used for a variety 
of indications, recently including nonmalig-
nancy [10]. Perhaps an underappreciated aspect 
of PDT is that this tumor-ablative therapy can 
be performed in relatively simple conditions, 
thus allowing for outstanding cancer treat-
ment in regions where state of the art oncologic 
therapy remains rare [11]. To better appreciate 
where PDT is headed we will look at its current 
strengths and weaknesses.
Photosensitizers
The transfer of light energy is the basis of life on 
earth; therefore, it should come as little surprise 
that a myriad of naturally occurring as well as 
synthetic agents have this capacity [12]. When 
this transfer of light energy results in what is 
classically termed a type II oxidative reaction, 
the transfer agent is termed a photosensitizer 
(PS) (Figure 1). Very few PSs have been rigor-
ously tested for clinical application and only 
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a handful have passed clinical trials to allow 
for regulatory approval for patient treatment. 
Furthermore, some PSs have passed regulatory 
approval in some countries, but not others, 
and are therefore unavailable for patients. This 
limited availability creates a significant impedi-
ment in the pathway to a potentially important 
oncologic intervention. It does the patient and 
practitioner little good to have potentially out-
standing PSs that are not available when they 
are required.
Currently available PSs may have signifi-
cantly different structures but most come from 
several inter-related families of dyes, porphyrins 
and chlorines [13]. These PSs share numerous 
clinical characteristics that allow for treat-
ment success, but also have significant short-
comings, which when resolved through scien-
tific advance, will bode well for future PDT. 
Currently, depending on the definitions of suc-
cess, a clinically successful PS will have some or 
all of the following characteristics:
n	Commercial availability
n	Easily synthesized to allow for commercial 
production
n	Synthetic purity for regulatory approval
n	Amphylicity for tissue penetration
n	Chemical stability for transport and 
reconstitution
n	Concentration in target tissue
n	Clearance from nontarget tissue
n	No dark toxicity
n	Clinically useful half-life in tissue
n	Clinically useful activation energy and 
wavelength
n	High quantum yield of triplet formation from 
the excited state
n	High molar extinction coefficient
n	Appropriate triplet lifetime to allow the triplet 
PS to interact with ground state triplet oxygen
n	Various modes of application: topical, oral 
and intravenous
The difficulties in meeting these goals are 
myriad. From a pharmaceutical production 
standpoint, the ability to produce a stable drug 
that is identical from batch to batch and can be 
synthesized in a cost-effective manner is critical. 
For the patient, these concepts are irrelevant as 
what the end user requires is a relatively pain-
free and effective therapy. For the scientist, the 
ability to determine the biological and physical 
effects may be pre-eminent. For the clinician, 
the need is for reliable clinical outcome with 
minimal short- and long-term morbidity. With 
these disparate requirements, it is a wonder 
that any drug can be successful, yet multiple 
PSs have passed muster via successful clini-
cal trials, as will be highlighted. PSs that have 
been employed in oncology are shown in Table 1. 
The particular oncologic application for each is 
examined in detail in reference [12]
Currently, only the following PSs are widely 
available for oncologic indications and it is 
worthwhile to review how they fit into the 
current PDT paradigm.
Photofrin®
This is a proprietary mix of porphyrin mono-
mers, dimers and oligomers, all of which are 
required for PDT activity in the patient [14]. 
This lack of synthetic purity would likely pre-
vent Photofrin® (Axcan Pharma, Inc., QC, 
Canada) from achieving regulatory approval 
today. The drug can be synthesized in a cost-
effective manner and is reconstituted under 
a wide variety of conditions allowing for use 
even in the developing world. It is not a very 
active PS, requiring prolonged treatment times 
(minutes to hours), though treatment itself is 
painless. The drug is delivered as an intra-
venous infusion, generally of 2.0 mg/kg, and 
PDT is initiated at 48 h post injection to allow 
for accumulation in target tissue and some 
Figure 1. The photodynamic therapy process. Light of the appropriate intensity 
and wavelength activates the PS. The activated PS may generate a type II reaction, 
a type I reaction or lose energy via the release of visible light (fluorescence). 
PS: Photosensitizer.
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clearance from ‘normal’ tissue. Various wave-
lengths of light activate Photofrin, including 
400 nm (blue light), 540 nm (green light) and 
630 nm (red light). As red light may penetrate 
tissue to 1 cm depth, this is often employed for 
most clinical oncologic applications. However, 
significant PS accumulates in the skin, requir-
ing approximately 6 weeks of photosensitivity 
precautions (i.e., avoidance of sunlight, room 
light is acceptable) meaning a significant life-
style change for that period of time. Despite 
these shortcomings this PS has been available 
for two decades and has treated thousands of 
patients. It has achieved worldwide regulatory 
approval and was the basis of growth for onco-
logic PDT. The skin photosensitivity period 
and long treatment times have limited this PS, 
particularly in regions where other PSs have 
become available.
Foscan®
Foscan® is a highly active synthetic chlorin-
based PS and treatment may require a minute 
or less [15]. In addition, the drug is so active 
that even room light may activate it, so patients 
must stay in a dimly lit room for approxi-
mately 24 h after intravenous introduction. A 
drug dose of 0.1 mg/kg and light of 652 nm 
is usually employed. In contrast to Photofrin, 
the treatment itself can be relatively painful. 
Furthermore, approximately 4 days post-infu-
sion is required to achieve maximum differ-
ential in drug accumulation between tumor 
and normal tissue. Still, at the current drug 
dose/light dose little, if any, selectivity between 
normal and tumor tissue is seen. While widely 
available and widely used in Europe this PS did 
not achieve US FDA approval [12]. Despite this, 
Foscan has become the preferred PS to treat 
tumors of the head and neck, owing in large part 
to its rapid treatment time and shorter window 
of cutaneous photosensitivity (<2 weeks).
Aminolevulinic acid
Aminolevulinic acid (ALA) is a prodrug that 
is enzymatictly converted to protoporphyrin 
IX, an active PS [16]. ALA may be introduced 
intravenously or orally, but has found great suc-
cess in a topical form. This allows for highly 
specific PDT on areas of the skin placed in 
contact with the PS and eliminates generalized 
photo sensitivity reactions. The PS itself is widely 
commercially available in various forms and is 
currently the PS frequently used for cutaneous 
applications [12]. The oral and intravenous forms 
have produced excellent outcomes for esopha-
geal cancer, for example, but when delivered in 
this manner, may rarely result in gastrointesti-
nal toxicity (nausea). As a topical formulation, 
tissue penetration is only several millimeters so 
blue light (400 nm) is used. For deeper penetra-
tion oral ALA (20 mg/kg) 3–4 h prior to PDT 
and red light are used. When taken orally, 72 h 
generalized skin photosensitivity is expected.
While these three PSs allow clinicians a lim-
ited choice, they also complement each other in 
terms of clinical indications. Clearly, much room 
for improvement exists for future PSs in PDT.
Table 1. Photosensitizers currently used in clinical oncology.
Drug Substance Manufacturer Ref.
Photofrin® HpD Axcan Pharma Inc. (QC, Canada) [101]
Photogem® HpD Moscow Research Oncological Institute 
(Moscow, Russia)
[102]
Levulan® ALA DUSA Pharmaceuticals, Inc. (MA, USA) [103]
Metvix® M-ALA PhotoCure ASA (Oslo, Norway) [104]
Hexvix® H-ALA PhotoCure ASA [105]
Visudyne® Verteporfin Novartis Pharmaceuticals (Basel, 
Switzerland)
[106]
Antrin®, Lu-Tex Lutexaphyrin Pharmacylics (CA, USA) [107]
Foscan® Temoporfin Biolitec Pharma Ltd (Dublin, Ireland) [108]
LS11, Photolon®, 
LitxTM, 
ApoptosinTM, 
Laserphyrin
Talaporfin Light Sciences (Washington DC, USA) [109]
Photochlor HPPH Roswell Park Cancer Institute (NY, USA) [110]
Photosens® Phthalocyanine General Physics Institute (Moscow, Russia) [111]
Pc4 Phthalocyanine Case Western Reserve University (OH, USA) [112]
Tookad Bacteriochlorophyll The Weisman Institute of Science  
(Rehovot, Israel)
[113]
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Light sources
With the introduction of laser light sources, 
more accurate and reproducible illumination 
became possible, as lasers could be tuned to 
the appropriate wavelength to activate a spe-
cific PS [17]. Furthermore, many of the com-
mercially available lasers had built-in dosim-
etry tools, allowing the clinician to better 
calculate delivered light dose for more uni-
form and reproducible therapy. In addition, 
current lasers, particularly diode lasers, have 
become portable without the need for spe-
cial cooling or electrical requirements, thus 
also improving access to PDT in developing 
regions of the world [11,18]. This technologi-
cal advance allowed for unprecedented growth 
of PDT [19]. More recently, light-emitting 
diode (LED) light sources have become com-
mercially available [17,19,20]. These are far less 
expensive than lasers, again allowing PDT to 
be brought to a worldwide audience in a more 
cost-effective manner. Of equal importance, 
fiber optics for lasers and flexible LEDs are now 
available, which can easily fit the apertures of 
endoscopes and biopsy needles; therefore, light 
can now routinely be brought into deep tissues 
via the bronchoscope, endoscope or through 
computed tomography-guided biopsy tech-
niques, allowing for PDT of previously inac-
cessible tumors [21]. Prior to these advances, 
only the PS could reach these tumors, but the 
required illumination to activate the PS was 
not available. Now, with minimally invasive 
technology and illumination sources designed 
for these tools, a new frontier of PDT of deep 
tumors of the CNS [22], head and neck [23], 
thorax [24], and abdomen [25], among other 
anatomic regions [26], has developed.
Photodynamic reaction
The PDR is considered to be the successful 
creation of a type II redox reaction, which 
creates free radicals via singlet oxygen gen-
eration [27]. Therefore, PSs were chosen that 
favored this pathway of light activation. In 
reality, light energy can activate a PS in many 
ways (Figure  1) [28]. Another pathway occurs 
through a type I reaction. Here the light 
energy transfer results in target damage and 
ablation through a superoxide radical anion. 
Many PSs exist that allow for both type I and 
II pathway activation, making this use of these 
PSs advantageous. As tumors considered resis-
tant to therapy are hypoxic, the use of direct 
toxicity (type III reaction) may be of clinical 
utility. A subtle point must be observed. As 
will be discussed, most current PS accumulates 
in membranes of cells and subcellular organ-
elles. Therefore PDT appears to be nonmuta-
genic as it damages membranes, not DNA. By 
favoring a type III reaction one may actually 
create DNA damage and change PDT from 
a nonmutagenic treatment to a potentially 
mutagenic therapy. Two other clinically rel-
evant pathways may also be activated by the 
introduction of light energy to the PS. One is 
fluorescence and the other in absence of oxygen 
is phosphorescence. Both produce visible light 
as the introduced light energy fades. Clinically, 
this can be exploited to allow for visualiza-
tion of the tumor’s bed or extent. This may 
assist in demarcating tumor extent for PDT or 
for the surgeon’s knife [29]. This fluorescence 
phenomena may be used for photodiagnosis 
or optical biopsy, both of which are in their 
infancy [30]. Here, the difference between flu-
orescence/optical signal of tumor compared 
with normal tissue is exploited to assist in 
disease diagnosis.
Current clinical state of the art
Despite the limitations in PSs, light sources and 
the PDR, clinical PDT has continued to grow 
owing both to the simplicity of therapy and 
excellent clinical success, so it is worthwhile to 
analyze current clinical outcomes. 
The topically applied PS, ALA and its related 
PS, methyl aminolevulinate (MAL) have found 
a growing niche in the treatment of cutaneous 
diseases [31]. As both ALA and MAL have very 
limited tissue penetration, PDT is limited to 
superficial lesions. In multiple well-designed 
clinical trials ALA and MAL PDT has been 
shown to eliminate actinic keratoses and super-
ficial basal cell tumors quite effectively [32]. 
What has also been commented upon is the 
superior cosmetic outcomes patients achieve 
as compared with other forms of treatment 
such as curettage, freezing and other abla-
tive techniques [33]. This superior cosmetic 
outcome forms a basis for PDT’s future use 
in dermatology. Similarly, ALA-based fluo-
rescence and PDT hold great promise in the 
treatment of other superficial malignancies 
where functional outcome is critical, most 
notably for in  situ bladder cancer where cur-
rent therapies often ultimately result in the 
loss of this organ’s function [34]. ALA has 
also been used to assist in fluorescence guided 
resection. Both improved rates of clear margins 
and tighter resections sparing normal tissue are 
possible [35,36].
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Foscan-based therapies have achieved excellent 
response for select primary and recurrent tumors 
of the head and neck [37]. Multiple trials report 
excellent tumor ablation for early stage head and 
neck primaries where risk of lymphatic metas-
tasis is low (as PDT cannot yet treat the nodal 
chains). Significantly, PDT results in excellent 
functional preservation [38].
An important PDT trial also revealed excel-
lent palliation for head and neck patients who 
failed surgery and radiation and had symp-
tomatic local recurrence [39]. Most patients 
achieved an excellent level of symptom con-
trol and a minority had re-establishment of 
tumor control. As tumor control for head and 
neck cancer is tantamount to survival this 
was a great benefit. Similarly, Foscan demon-
strates great potential for photodiagnosis and 
fluorescence-guided surgery in the brain [40].
Photofrin has been available for several 
decades and has a large body of literature 
reporting high tumor ablation rates with 
excellent functional outcomes [41]. Long-term 
data reveal its ability to preserve esophageal 
function with tumor elimination for primary 
esophageal tumors as well as Barrett’s esopha-
gus [42,43]. A large head and neck population 
has achieved function-sparing therapy [44]. 
Similar excellent outcomes from large ran-
domized trials are reported for both early and 
obstructive lung cancers [45,46]. PDT allows for 
rapid tumor control with excellent functional 
preservation. Photofrin PDT has developed 
a niche for breast cancer patients with chest 
wall recurrence who have failed salvage sur-
gery, radiation and chemotherapy [47,48]. Here, 
despite extensive prior therapy, tumor ablation 
with good wound healing is possible. Recently, 
Photofrin PDT has demonstrated a doubling of 
survival in randomized trials for patients with 
bilary cholangiocarcinoma [49–51]. Prolonged 
survival with a high quality of life is possible 
through outpatient treatment. The use of 
Photofrin in fluorescence-guided surgery and 
PDT have made great gains. Further prog-
ress has been made in treating CNS cancers, 
where the need for function-sparing surgery is 
critical [22,52]. 
While clinical outcomes can be excellent in 
terms of tumor control and functional preser-
vation, clinical PDT therapy still has a number 
of relative shortcomings. With the exception of 
Photofrin, the actual treatment can be painful, 
which may prevent some patients from consent-
ing. With the exception of topical ALA, sun-
light restrictions may also prevent patients from 
choosing this therapy. The two-step stage of 
infusion and then waiting hours-to-days for the 
drug to accumulate into target tissue and clear 
from normal tissue makes it difficult to schedule 
actual treatment. 
However, most difficult is the current lack 
of real time dosimetry [53,54]. Dosimetry is the 
means to optimize therapeutic outcome and 
minimize normal tissue effects [55]. In con-
trast to light dosimetry, radiation dosimetry 
has been well worked out, resulting in dra-
matic improvement in radiotherapy. No such 
improvement has yet been seen for PDT, so 
clinically, a significant acute tissue reaction 
generally occurs during the actual PDT ses-
sions for both tumor and surrounding normal 
tissue. While possibly of limited consequence 
for PDT of the skin, this can lead to obstruc-
tion of the airway following PDT of the 
lungs. More accurate dosimetry to minimize 
acute normal tissue reactions and enhance 
long-term normal tissue healing is the key to 
future dosimetry for PDT. The combination 
of these shortcomings has limited the growth 
of PDT. 
Of consequence too, is the fact that sur-
gery and radiation therapy, the two standard 
choices for local tumor control, have dramati-
cally improved technology (e.g., robotics and 
radio surgery) so that minimally invasive, 
highly functional outcomes with these treat-
ments are much more common today than 
even a decade ago. As minimally invasive and 
functional sparing was a key component of 
the original argument for introducing PDT 
to the clinic over conventional surgery and 
radiation, this argument has been weakened, 
albeit only in countries with highly developed 
medical infrastructure.
Future PDT
The future of PDT will require a reana lysis of 
what a PS is, what a light source is and what 
can be done to manipulate the PDR. Today the 
practitioner of PDT employs tools quite similar 
to those of PDT pioneers and delivers therapy in 
a fashion not much different than that offered 
100 years ago. It is doubtful that the same will 
be said even by the end of this decade.
Future PSs
The current group of PSs accumulate in target 
tissue for reasons that remain unclear but can be 
attributed to various receptors and the micro-
environment of tumors [56]. Clearing of PS is 
thought to be based on improved circulation 
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in normal tissue compared with tumors [57]. To 
improve selectivity this paradigm must be fully 
elucidated and manipulated. 
Currently, it is believed that most PSs travel 
intravenously as complexes of serum pro-
teins [58]. At this small size they may not gener-
ally be recognized by the reticulo-endothelial 
system, though PS may still undergo uptake 
by the Kupfer cells of the liver. The PSs are 
then taken up preferentially by rapidly prolif-
erating tissue, such as tumor tissue. This may 
be through a mechanism similar or identical 
to the low-density lipoprotein receptor. Leaky 
neovasculature will also allow for enhanced 
permeability and accumulation of the PS in the 
tumor region. Designing future PSs to bind to 
tumor-specific receptors or by conjugating PSs to 
compounds that bind to these regions are fertile 
means to improve PS specificity. Other areas of 
exploration include localizing PSs to hypoxic 
regions, which are considered relatively resistant 
to current therapy, and altering the PS so that it 
may directly involve the immune system rather 
than avoiding it as current intact PSs seems to 
do [59,60]. 
The current group of PSs can be further 
exploited to improve both future PDT and 
oncologic therapy through their ability to image 
tumors and by combining the PS with additional 
therapeutic agents.
Imaging
The structure of current PSs is similar to con-
trast agents used in radiology so it would not be 
out of the question to use current PSs as both 
diagnostic and therapeutic agents [61]. The PS 
could be employed to better define tumor beds 
through its imaging characteristics, and then 
assist in ablation via PDT. Imaging could be 
by anatomic localization for computerized axial 
tomography scanning or MRI, or in a more 
ingenious fashion via biologic imaging. If PSs 
were designed to accumulate in hypoxic regions 
this could be a means to better define hypoxic 
areas of tumors that may require additional 
therapy. Furthermore, changes in PS activity 
could be used as a means of determining treat-
ment success or failure, which will be discussed 
later [62]. The fluorescence capability of most 
PSs is under- utilized and could be employed to 
assist in improving treatment targeting or even 
delineation of margin status for surgery [63]. It 
should be noted that PDT and fluorescence are 
competing pathways, so highly efficient fluo-
rescing agents may be poor PSs and vice versa. 
Fluorescence-guided surgery may better allow 
the surgeon to spare normal tissue and achieve 
clear tumor margins. This has already been dem-
onstrated to be feasible for cutaneous tumors and 
bladder cancer [64,65]. Current PSs may also be 
employed as a one-two punch against tumors, 
using both surgery to remove gross disease and 
PDT to eliminate microscopic extensions. 
Conjugating
Conjugating current PSs is another means to 
improve outcomes [66–68]. The conjugate may 
be radioactive for additional tumor destruction, 
or act as a tag to have an additional means to 
detect cellular function and turn pathways 
on or off. This would have both clinical and 
scientific implications. A particularly promis-
ing conjugate is based on a PS attached to a 
chemo therapeutic agent. The PS and chemo-
therapeutic agents accumulate in the tumor 
membrane and via illumination lead to PDT as 
well as release (photolysis) of the chemothera-
peutic agent [69,70]. The conjugates might be 
an antibody, imaging agent, or perhaps most 
exciting, a nanoparticle.
Nanoparticles
Nanoparticles are likely to represent the next 
generation of PSs [58]. Current PSs require 
amphylicity, the ability both to travel unhin-
dered through the blood system and then to 
localize and be introduced into the target tis-
sue. While several of the current PSs may have 
this ability, many other potentially outstand-
ing PS agents lack either the ability to readily 
travel through the body or to be concentrated 
appropriately at the target. This is one area 
where nanoparticles will play an important 
role. By encapsulating current PSs within well-
designed nanoparticles, the ability to traverse 
the body intravenously will become possible. 
Furthermore, this will allow for precise local-
ization at specific sites within the tumor or neo-
vasculature. Therefore, chemists will be able to 
synthesize highly efficient PS agents that previ-
ously could not be used owing to issues such as 
hydrophobicity, lipophobicity, clumping, non-
target toxicity and dark toxicity among numer-
ous other inappropriate characteristics of cur-
rent agents [71]. The nanoparticle would not only 
be used for targeted transport but also to prevent 
PS from concentrating, for example, in skin. In 
reality the biological and physical activity of the 
PS would be controlled via the nanoparticles, so 
tissue half-life and other characteristics would 
be based on the designed nanoparticles rather 
than the variability associated with current PSs. 
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The nanoparticle could be created to bring the 
PS to very specific sites within tumors through 
a variety of techniques. This may also assist in 
better defining the oncologic process, perhaps 
ultimately creating an on–off switch to reverse 
malignant changes [72]. 
One may even create paramagnetic PS 
nanoparticles that would be directed to tumors 
by magnetic means [73]. The magnetic field 
could also be used to heat the tumor via hyper-
thermia of the nanoparticles in addition to light 
illumination via PDT. Future PS–nanoparticles 
conjugates may play a myriad of diagnostic and 
therapeutic roles. These may include fluorescing 
in the presence of a particular protein, toxin or 
even malignant cell. If designed appropriately, 
the PS would then be activated to destroy the 
offending target.
Light sources
As light sources have miniaturized and become 
portable, PDT has expanded. With the con-
tinuing dramatic advances in light production, 
this aspect of PDT will become highly refined 
(Figure 2) [17,21,74]. While lasers have remained the 
mainstay for much of PDT they are expensive 
and still relatively large. By contrast, LED tech-
nology has come to the forefront of PDT. These 
tiny and often battery-operated light sources can 
now easily fit though scopes and biopsy channels 
for deep tissue illumination. They can also be 
designed for easy surface illumination through 
various arrays. The advance here is the highly 
portable energy source, for example, battery 
power, which is self contained. Now the patient 
can be mobile during illumination. This allows 
for the realization of prolonged outpatient illu-
mination as well as metronomic repeated illumi-
nation [75]. Originally, PDT developed as a single 
intense illumination session, mainly because it 
was difficult to illuminate repeatedly, particu-
larly for deep lesions. It is well known from 
most radiotherapy and chemotherapy protocols 
that fractionation of dose delivery may allow for 
excellent tumor control and diminished normal 
tissue damage. Therefore, the new ability for 
prolonged light and multiple fractions of illu-
mination may further improve PDT outcomes or 
normal tissue recovery [76]. Even more impressive 
is the development of organic LED technology 
(Figure 3) [58]. These light sources can be made 
from films that could be implanted to cover 
an entire tumor, opening new and innovative 
illumination pathways. Ultimately, dissolvable 
light sources with built-in timers that turn on 
and off when in contact with the PS could be 
created, which would be a truly fantastic means 
to offer future PDT. This may be possible based 
on nanoparticle light sources.
Conceivably, a PS–light source conjugate 
could also be created. Illumination could be 
started upon contact with tumor or through 
additional energy brought in via magnets (MRI), 
heat or radiation from other energy sources. 
Figure 2. An implantable light source for prolonged or metronomic 
photodynamic therapy (Light Science Oncology [109]). 
Reproduced with permission from [21].
Figure 3. A possible future light source of flexible and film-like material 
composed of organic light emitting diodes. 
Reproduced with permission from [114].
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Here, highly accurate localization of treatment 
would also be possible through two-photon tech-
nology [77]. What is notable in this situation is 
that the PS and light source are so close together 
that shorter wavelengths of light, which travel 
only a few millimeters, could be used to activate 
the PS. This is in contrast to today’s PSs, which 
use longer wavelengths of light, which, owing to 
deeper tissue penetration, may cause unneeded 
PDT in tissue centimeters from the target. The 
future use of shorter light wavelength could 
allow for far less collateral damage to normal 
tissue regions that should not be illuminated.
Photodynamic reaction
As mentioned, current PSs favor a type II path-
way, but the other pathways (type I, fluorescence 
and so on) remain an underutilized avenue to 
improve PDT. Future PDT will also likely better 
exploit the location of the PDR. Achieving PDR 
exclusively in vessels will allow for vascular shut-
down [78]. Tumor cell PDR may allow for apop-
totic response and/or necrosis [59]. In the future 
these locations will be better controlled depend-
ing on the specific clinical situation. More specific 
localization of the PDR onto specific sub cellular 
membranes such as mitochondria may also influ-
ence the type of clinical outcomes seen with PDT, 
an area of active exploration [9]. Release of cyto-
kines may allow for immune response via select 
tumor-destructive pathways, resulting in a sys-
tematic immune response [79]. Thus PDT-based 
vaccines using antigen presentation and cytokine 
release are distinct possibilities for the future [80]. 
By modulating the PDR, one may also prevent 
immune stimulation when indicated.
It would not seem unreasonable that the PDR 
could be used for tissue regeneration instead 
of ablation [81]. The outstanding cosmetic out-
comes from PDT may well result from this. 
Furthermore, the combination of fluorescence 
and PDR can be used to study the steps in the 
oncologic process and development of metastasis. 
As stem cells appear to be involved in tumorigen-
esis and healing, we may be able to use both PDR 
and PDT to better define these complex cells 
and their differentiation pathways and processes. 
Conceivably too, with nano particles, quenchers 
of the PDR could be created to further define 
regions for protection instead of regions for treat-
ment. Real-time dosimetry may well be achieved 
via nanoparticle dosimeters, which would turn 
the PDR off when the tumor was ablated, similar 
in concept to nanoparticle-based labs on a chip, 
which can accurately determine the presence of 
malignant cells, among other possibilities.
Future perspective
The future direction of scientific PDT will no 
doubt include the delineation of accurate and indi-
vidualized therapy through improved PS agents, 
which may be enhanced through nanoparticles 
and conjugates, innovative light sources and better 
control of the PDR. These tools will also allow 
for better definition and understanding of the 
immune system and stem cells not only in terms 
of tumorigenesis but also in terms of healing.
The future direction of clinical PDT will 
require the availability of PS and tools for treat-
ment, which is not guaranteed. Most PDT com-
panies are relatively small, so this is of great con-
cern. Fortunately, some governments have seen 
the value of PDT in terms of cost–effectiveness 
and have made the future of clinical PDT more 
reliable [11,18,82]. It has become clear that PDT 
offers excellent function-sparing tumor ablation 
therapy without the need for expensive invest-
ment in surgical suites, robots, high-end linear 
accelerators and other such devices. This has 
allowed for unprecedented growth of PDT in, 
for example, Brazil [11]. While PDT was designed 
for tumor ablation it has also found use in der-
matology not only for therapy of superficial 
malignancies but now more often for outstand-
ing cosmetic purposes and facial rejuvenation. 
This regeneration of skin may form the basis not 
only for wound healing but perhaps for tissue and 
organ regeneration. The burgeoning exploration 
of PDT as an immune modulator may find this 
clinical application growing in immunotherapy 
and vaccination. The ability to destroy plaques 
and neovasculature will become common.
Furthermore, as the PDR is not limited to 
tumors [83], one will see PDT growing as a means 
of antimicrobial therapy, antiviral therapy and 
antifungal therapy; perhaps even as a means to 
sterilize microorganisms that cause food-borne ill-
ness and also to bind and destroy poisons. While 
developed heavily as an oncologic intervention, 
PDT has now grown far beyond this indication, 
which may be looked back on as a fundamental 
stepping stone to a myriad of other uses.
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Executive summary
Current photodynamic therapy
n	Photodynamic therapy (PDT) is a tumor ablative, yet function-sparing oncologic therapy.
n	PDT consists of an applied photosensitizing agent that, when activated by the appropriate intensity 
and wavelength of light, leads to the cytotoxic and vascular toxic photodynamic reaction (PDR).
n	Photosensitizing agents may be natural or synthetic.
n	Currently available photosensitizer (PS) agents are dyes, porphyrins or chlorines.
n	While many PSs exist or can be created, few have been employed in clinical trials and even fewer 
are commercially available.
n	Successful PS agents are easily synthesized, stable, nontoxic until activated by light, concentrate to 
a degree in tumors, clear normal tissue and allow for reliable tumor ablation.
n	All commercially available PS have drawbacks, including normal skin photosensitivity, prolonged 
treatment times and pain on illumination.
n	Light sources are required to activate the PS.
n	Each PS has a unique light wavelength and intensity requirement.
n	Lasers and light emitting diodes are commercially available to activate each PS.
n	Sunlight is a broad spectrum, intense light source that can inadvertently activate the PS in  
sunlight-exposed anatomy, so photosensitivity precautions are critical.
n	Optic fibers allow light sources to be brought to virtually any tissue.
n	When a PS is activated by light the PDR may occur.
n	The PDR is a type II reaction that generates highly toxic singlet oxygen species.
n	As PSs generally accumulate in cell membranes, the PDR occurs here.
n	Despite the shortcomings of currently available PSs and light sources, PDT has demonstrated an 
excellent effect in a variety of tumors of the skin, head and neck, lung, esophagus, breast and other 
tumor sites.
n	PDT for cholangiocarcinoma has doubled patient survival times.
Future PDT
n	The current generation of PSs can be better employed.
n	This includes their use as imaging tools as well as cytotoxic tools.
n	Current PSs have fluorescence capability, which allows for tumor demarcation, assisting the surgeon.
n	The use of fluorescence and PDT will improve tumor targeting.
n	Changes in fluorescence may be a means to improve treatment dosimetry as well as accuracy.
n	Future PS agents may be designed for specific receptors.
n	Future PSs may be encapsulated by nanoparticles (NPs) to improve targeting and tissue penetration.
n	NP–PS conjugates that also allow for imaging as well as therapy may be synthesized.
n	NP–PS may, for example, be paramagnetic. This would allow MRI imaging and magnetic fields to direct 
the NP to the tumor. In addition to PDT, the magnets could heat the NP to allow for hyperthermia.
n	Future light sources will be miniaturized.
n	These miniature light sources will be implantable for prolonged illumination and metronomic therapy.
n	Implantable and dissolvable organic light emitting diode light sources with built-in timers will be 
created that conform to tumor beds.
n	NPs may serve as the light source.
n	NPs could be turned on or off by external energy supplies such as magnetic fields or radiation.
n	The PDR will be better controlled in the future with greater ability to limit this to tumor beds.
n	By controlling the PDR, one may favor apoptosis with a truly local response or necrosis with release of 
cytotines resulting in an immune response.
n	PDT-based vaccination will become possible.
n	As PDT offers excellent wound healing, exploiting this pathway may generate tissue  
regenerative approaches.
n	Stem cells may be tagged by PS, and the pathways for tumor genesis as well as healing will become 
clearer through fluorescence imaging.
n	PDT of the future will include the treatment of nonmalignancies, such as bacterial, viral and 
fungal infections.
n	Future PDT will include emphasis on cutaneous rejuvenation and elimination, for example, of unwanted 
tissue such as plaque, neovasculature, scar and fibrosis.
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